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Background
Alpha-fetoprotein (AFP) is a plasma protein that is produced
by the liver and the yolk sac during fetal development. In
adults, an elevation in this protein can be exclusive to
specific malignancies such as hepatocellular carcinoma,
yolk sac tumors, and metastatic disease to the liver. In the
clinical setting, an elevated AFP level and a liver mass
(masses) translate to a diagnosis of hepatocellular carcino-
ma. Gastric adenocarcinoma is an aggressive malignancy
that has a poor prognosis and has a potential for early
metastatic spread [1]. There have been some case reports
in the literature that have described elevated AFP levels in
gastric adenocarcinoma with metastasis to the liver and
hepatoid adenocarcinoma of the stomach. Here, we report
an unusual case of nonmetastatic gastric adenocarcinoma
with local compression on the liver and elevated AFP levels
in a previously healthy woman.
Case Presentation
A 33-year-old woman from Saint Vincent Island presented
to the emergency department with complaints of 6-month
history of epigastric mass and pain, 15-lb weight loss, and
poor appetite. She stated that she was evaluated by the local
physician in the Caribbean and was told that she has a cyst.
No other further work-up was done. She denied fevers,
chills, change in the color of the urine or stool, nausea, or
vomiting. She was an ex-smoker and quit 10 years ago. She
denied alcohol intake, any prescribed or illicit drug use,
drug allergy, or any significant family history.
Vital signs revealed a pulse of 82 beats/min, blood pressure
of 101/62 mmHg, respiratory rate of 20 respirations/min, and
normal temperature. On physical exam, the patient appeared
cachectic. Rest of the physical exam was significant for jaun-
dice, scleral icterus, and a 14×16 cm non-tender epigastric
mass. Laboratory tests revealed the following: white blood
count of 16,000/μL, hemoglobin of 9.9 g/dL, platelet count of
882,000/μL, total bilirubin of 8.7 mg/dL, alkaline phosphatase
of 590 units/L, albumin of 2.2 g/dL, LDH of 374 units/L, INR
of 1.5, and normal glucose, electrolytes, renal function, amy-
lase, lipase, and rest of the liver function tests. Tests of tumor
markers revealed an AFP level of 1,451 ng/dL and normal
carcinoembryonic antigen, CA 19-9, and βHCG. CT scan of
the abdomen with oral and intravenous contrast revealed a
heterogeneous upper abdominal mass measuring 12.6×11.7×
11.4 cm inseparable from the lesser curvature of the stomach,
compressing the liver hilum, periportal vessels and causing
mild to moderate intrahepatic biliary ductal dilatation (Fig. 1).
Ultrasound of the abdomen also confirmed these findings.
Esophagogastroduodenoscopy revealed candidal esophagitis
and a large smooth intramural or extrinsic mass arising from
the lesser curvature of the stomach. Histopathological exami-
nation of the biopsy of the gastric mass was inconclusive.
Histopathological examination and immunohistochemistry of
CT-guided fine-needle aspiration of the abdominal mass re-
vealed CK7+ rare positivity, CK20+, villin+, CDX-2+, and
negative for CA 19-9 and CA 125. AFP stain was negative.
These findings were consistent with upper gastrointestinal,
pancreatobiliary, or bladder neoplasm. Ultrasound of the pelvis
did not reveal any masses. Serology for Helicobacter pylori
was positive, and treatment was initiated. She was also treated
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for candidal esophagitis. Further testing revealed sequential
elevations in the total bilirubin, direct bilirubin, and the alkaline
phosphatase levels. The patient became more cachectic and
could not maintain adequate oral intake. Parenteral nutrition
was started. She also underwent a laparoscopy and core biopsy
of the abdominal mass, and the histopathological examination
and immunohistochemistry revealed adenocarcinoma with ex-
tensive necrosis most consistent with upper gastrointestinal
primary neoplasm. An independent external pathology labora-
tory also confirmed the same findings. Jejunostomy tube was
also placed for feeding, and parenteral nutrition was
discontinued. Due the rising bilirubin levels, a transhepatic
cholangiogram was performed with placement of an
internal/external biliary catheter for drainage. The bilirubin
levels decreased to a nadir of 12.5 mg/dL after the placement
of the biliary drainage catheter. Due to the abnormal bilirubin,
the patient was not a candidate for the conventional gastric
adenocarcinoma chemotherapy regimens, and the plan was to
start chemotherapy consisting of weekly gemcitabine at a re-
duced dose to adjust for the bilirubin levels. She received
gemcitabine at the reduced dose of 800 mg/m2. Pain control
was achieved with intravenous hydromorphone via the patient-
controlled analgesia pump. Soon after the administration of
chemotherapy, there was an improvement in the clinical and
laboratory parameters. However, after a few days, there was
deterioration in the patient’s mental and respiratory status. CT
scan of the head and the chest did not reveal metastasis or
pulmonary embolism. Ammonia level was elevated, and
lactulose was administered. She was not able to receive any
further chemotherapy, and efforts were made to keep her on
comfort care. Eventually, the patient was discharged in stable
condition as per the family’s wishes to the Saint Vincent Island.
Discussion
Gastric cancer is an aggressive malignancy with a poor prog-
nosis. In the USA, gastric cancer ranks 14th in incidence
among the other malignancies [2]. It is estimated that 21,320
people will be diagnosed with, and 10,540 people will die of
gastric cancer in 2012 in the USA [2]. Adenocarcinoma is the
most common histology and accounts for approximately 90–
95 % of all gastric cancer. The average age of diagnosis is 70,
but the incidence of proximal gastric adenocarcinoma has
risen dramatically in patients under the age of 40 over the last
two decades [2]. Risk factors for gastric adenocarcinoma
include advanced age, H. pylori infection, diets high in
smoked or preserved meats, male gender, chronic atrophic
gastritis, pernicious anemia, family history of gastric cancer,
familial adenomatous polyposis, and history of gastric adeno-
matous polyps. Gastric cancer carries a dismal prognosis.
Approximately 50 % of patients can be cured with localized
gastric cancer; however, it comprises only 10 to 20 % of all
cases diagnosed in the USA. Most patients have metastatic
disease at the time of diagnosis. The 5-year overall survival
rate ranges from very minimal for patients with disseminated
disease to almost 50 % survival for patients with resectable
localized distal gastric cancers. Even with apparent localized
disease, the 5-year survival rate of patients with proximal
gastric cancer is only 10 to 15 %.
In adults, AFP is a plasma protein produced mainly by
hepatocellular carcinoma. Less commonly, AFP elevation can
also be seen in other malignancies such as yolk sac tumor and
hepatoid adenocarcinoma. High AFP levels have also been
observed in gastric adenocarcinoma with synchronous hepatic
metastasis. Among all GI malignancies, an elevation of the
serum AFP level was reported in 1.3 to 15 % of gastric
cancers. Nonmetastatic gastric adenocarcinomas that secrete
AFP are rare. Fifteen cases (3.9 %) out of 387 with gastric
cancer showing elevation of AFP in serum was described in
one of the reports in the literature; liver metastasis was ob-
served in 12 (80 %) of these 15 cases [3]. AFP-producing
gastric cancers can be divided into three subtypes: (1)
hepatoid, (2) yolk sac tumor-like, and (3) fetal gastrointestinal
[4]. AFP is most commonly produced by the hepatoid
subtype. AFP-producing gastric cancers have a high prolifer-
ative activity, weak apoptosis, and rich neovascularization that
render them very aggressive with a poor prognosis [5]. Recent
reports have described that AFP-producing gastric tumors
express specific receptors and factors associated with mitosis,
cell movement, proliferative activity, and tumor progression
such as Ki-67, hepatocyte growth factor and its receptor, c-
Met, vascular endothelial growth factor (VEGF), and its iso-
form VEGF-C which may contribute to the poor prognosis
and drug resistance of these tumors [6, 7]. Benign conditions
such as cirrhosis, biliary obstruction, pregnancy, and viral
hepatitis can cause elevations in the serum AFP level. How-
ever, AFP values of greater than 500 ng/mL are unlikely due
to benign conditions [8].
Limited successful treatment options exist for AFP-
producing gastric cancer. Surgical resection is curative for
localized tumors, and approximately 50 % of patients who
underwent curative resection of the tumor will relapse with
Fig. 1 Image presentation of heterogeneous upper abdominal mass
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hepatic metastasis [9]. These tumors respond poorly to a
number of chemotherapy regimens. Some investigators have
reported that AFP-producing gastric cancer can be treated
successfully with neoadjuvant combination chemotherapy
with epirubicin, fluorouracil (5-FU), and leucovorin [10].
Some authors have also reported the use of the FLEP regimen
consisting of 5-FU, leucovorin, etoposide, and cisplatin for
inoperable stage IV gastric cancer [11]. The FLEP chemother-
apy regimen was more effective for stage IVAFP-producing
gastric cancer than for stage IV non-AFP-producing gastric
cancer, and it improved the prognosis of AFP-producing
gastric cancer due to downstaging of the cancer. Other che-
motherapy regimens consisting of 5-FU and paclitaxel have
also been described [12]. Gemcitabine and cisplatin combina-
tion regimens have shown moderate efficacy in advanced
gastric cancer [13].
Conclusion
Despite the utilization of aggressive multimodality treatment
options, the prognosis for AFP-producing gastric cancers re-
mains poor. Most patients who are diagnosed with AFP-
producing gastric cancer have liver metastasis at the time of
presentation. Our patient had AFP-producing gastric adenocar-
cinoma causing local compression on the biliary ducts,
resulting in intrahepatic biliary dilatation and elevated AFP
level. Repeat abdominal imaging did not reveal evidence of
hepatic metastasis. It is possible that the patient could develop
hepatic metastasis in the future. To the best of our knowledge,
this is the first case report in the literature of an AFP-producing
gastric adenocarcinoma without hepatic metastasis. We consid-
er this case to be unique in terms of the rarity of presentation.
Clinicians should be aware that although common tumors, such
as the ones described above, produce AFP, gastric cancer in the
nonmetastatic setting can also be a source of production of AFP.
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